Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Identification and characterization of a peptide with affinity to head and neck cancer.

Nothelfer EM, Zitzmann-Kolbe S, Garcia-Boy R, Krämer S, Herold-Mende C, Altmann A, Eisenhut M, Mier W, Haberkorn U.

J Nucl Med. 2009 Mar;50(3):426-34. doi: 10.2967/jnumed.108.058123. Epub 2009 Feb 17.

2.

Identification and evaluation of a new tumor cell-binding peptide, FROP-1.

Zitzmann S, Krämer S, Mier W, Hebling U, Altmann A, Rother A, Berndorff D, Eisenhut M, Haberkorn U.

J Nucl Med. 2007 Jun;48(6):965-72. Epub 2007 May 15.

3.

(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.

Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, Chen X.

J Nucl Med. 2007 Jul;48(7):1162-71. Epub 2007 Jun 15.

4.

Influence of chelate conjugation on a newly identified tumor-targeting peptide.

Mier W, Zitzmann S, Krämer S, Reed J, Knapp EM, Altmann A, Eisenhut M, Haberkorn U.

J Nucl Med. 2007 Sep;48(9):1545-52. Epub 2007 Aug 17.

5.

Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.

Chen X, Hou Y, Tohme M, Park R, Khankaldyyan V, Gonzales-Gomez I, Bading JR, Laug WE, Conti PS.

J Nucl Med. 2004 Oct;45(10):1776-83.

6.

Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.

Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH, Boerman OC.

Cancer Res. 2002 Nov 1;62(21):6146-51.

7.

Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.

Terry SY, Abiraj K, Frielink C, van Dijk LK, Bussink J, Oyen WJ, Boerman OC.

J Nucl Med. 2014 Feb;55(2):281-6. doi: 10.2967/jnumed.113.129668. Epub 2014 Jan 9.

8.

Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.

Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M.

J Nucl Med. 2001 Feb;42(2):326-36.

9.

Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.

Cai W, Chen K, Li ZB, Gambhir SS, Chen X.

J Nucl Med. 2007 Nov;48(11):1862-70. Epub 2007 Oct 17.

10.

microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.

Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, Gambhir SS, Chen X.

J Nucl Med. 2005 Oct;46(10):1707-18.

11.

Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.

Jung KH, Lee KH, Paik JY, Ko BH, Bae JS, Lee BC, Sung HJ, Kim DH, Choe YS, Chi DY.

J Nucl Med. 2006 Dec;47(12):2000-7.

12.

MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.

Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, van Dongen GA.

Cancer Res. 1993 Sep 15;53(18):4383-90.

13.

PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.

Niu G, Li Z, Xie J, Le QT, Chen X.

J Nucl Med. 2009 Jul;50(7):1116-23. doi: 10.2967/jnumed.109.061820. Epub 2009 Jun 12.

14.

Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules.

Sandström K, Haylock AK, Velikyan I, Spiegelberg D, Kareem H, Tolmachev V, Lundqvist H, Nestor M.

Cancer Biother Radiopharm. 2011 Oct;26(5):593-601. doi: 10.1089/cbr.2011.0981. Epub 2011 Aug 11.

PMID:
21834651
15.

Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.

Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stöcklin G, Schwaiger M.

J Nucl Med. 1999 Jun;40(6):1061-71.

16.

alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.

Yoshimoto M, Ogawa K, Washiyama K, Shikano N, Mori H, Amano R, Kawai K.

Int J Cancer. 2008 Aug 1;123(3):709-15. doi: 10.1002/ijc.23575.

17.

GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.

Schuhmacher J, Zhang H, Doll J, Mäcke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M.

J Nucl Med. 2005 Apr;46(4):691-9.

18.

In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging.

Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich DJ.

Bioconjug Chem. 2002 May-Jun;13(3):561-70.

PMID:
12009947
19.

[99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.

Decristoforo C, Faintuch-Linkowski B, Rey A, von Guggenberg E, Rupprich M, Hernandez-Gonzales I, Rodrigo T, Haubner R.

Nucl Med Biol. 2006 Nov;33(8):945-52.

PMID:
17127166
20.

111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.

Kumar SR, Deutscher SL.

J Nucl Med. 2008 May;49(5):796-803. doi: 10.2967/jnumed.107.048751. Epub 2008 Apr 15.

Supplemental Content

Support Center